AbbVie Gets CHMP Positive Opinion for Rinvoq in Rheumatoid Arthritis
October 18 2019 - 8:22AM
Dow Jones News
By Michael Dabaie
AbbVie Inc. (ABBV) said the European Medicines Agency's
Committee for Medicinal Products for Human Use adopted a positive
opinion for Rinvoq for the treatment of adult patients with
moderate to severe active rheumatoid arthritis.
The CHMP positive opinion is supported by data from the pivotal
Phase 3 SELECT rheumatoid arthritis program evaluating more than
4,400 patients, AbbVie said. The opinion will now be referred to
the European Commission for final approval, the company said.
In Phase 3 trials, upadacitinib improved signs and symptoms of
rheumatoid arthritis, inhibited radiographic progression and
improved physical function, AbbVie said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
October 18, 2019 08:07 ET (12:07 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024